June 11, 2015

Dr. Jeffrey Kasher Joins DrugDev as Chairman of Advisory Board

Senior executive brings 28 years of experience at Eli Lilly to help distinguished team of clinical research leaders guide the development of next-generation technology solutions

jeff-kasher-webKING OF PRUSSIA, PA & LONDON, Jun 11, 2015 – DrugDev continues to attract pharmaceutical industry visionaries to join its mission of developing innovative clinical technology solutions to help sponsors, CROs and sites do more trials together. Today, the company announced Jeffrey Kasher, Ph.D., has joined as Chairman of the DrugDev Advisory Board, a distinguished team of current and former clinical research executives from many of the leading pharmaceutical companies in the world.

Clinical research professionals attending the DIA 2015 51st Annual Meeting in Washington, D.C., are invited to attend a networking reception with Dr. Kasher at DrugDev exhibit booth #820 on Monday, June 15, from 4-6pm. Click here to RSVP.

Dr. Kasher is passionate about improving outcomes, bringing patient and research sites into the development process, and dramatically decreasing the time to market for promising drug candidates. He is known as a pharmaceutical development change catalyst who brings to the role 28 years of leadership experience at Eli Lilly, where most recently he managed a portfolio of innovative clinical development approaches to achieve 50% cost and time reductions to be realized over a five-year period beginning in 2017. His expert perspective includes direct experience with novel product development from bench through market launch, research and clinical trial leadership, innovation center startup, and new industry paradigm creation.

“Patients can no longer wait for us to get the drug development process right,” said Dr. Kasher. “With new technology at our disposal, it is our mandate as an industry to dramatically reduce the amount of time and money it takes to bring helpful new drugs to market. The team at DrugDev shares this mission, and I’m excited to help the company realize its goal of bringing technology solutions to drug developers that enable them to do more trials for the same or even reduced budget. Together, we’ll be able to get more drugs to the patients worldwide who need them, faster.”

“Jeff Kasher doesn’t work in clinical research innovation, he is clinical research innovation – and we couldn’t be more proud to have the man who essentially defined the term advising us on how to make the maximum impact on the way people run clinical trials,” said Ibraheem (Ibs) Mahmood, President and CEO of DrugDev. “I’m thrilled that our customers and partners, along with thousands of global sites and ultimately millions of patients, will benefit from the experience, advice and insight of a proven visionary who has dedicated his entire career to speeding the development and delivery of viable new drugs. The only negative thing I can say about Jeff, especially coming from a company devoted to achieving wellness, is he makes us all look bad by competing in Iron Man competitions and running marathons.”

Added Hugo Stephenson, MD, Executive Chairman of DrugDev, “We are on a mission to fundamentally change the clinical research process through industry-wide collaboration, standardization and a beautiful technology experience. Jeff Kasher’s focus on enabling companies to bring more drugs to market aligns perfectly with our goal to help companies do more trials, and his unrivaled experience creating disruption in all aspects of clinical research will be of immeasurable value in overcoming our industry’s essential challenge.”

In addition to his role at DrugDev, Dr. Kasher is President of Patients Can’t Wait, was a founding member of the TransCelerate Biopharma Operations Committee and the Avoca Quality Consortium, sits on the DPharm Europe steering committee and faculty, and is a member of Linking Leaders. In 2013 CenterWatch named Dr. Kasher one of the “20 Innovators Changing the Face of the Clinical Trials Industry.”

Dr. Kasher received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral Fellowship in Physiology at Yale University School of Medicine.

About DrugDev

DrugDev is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and powers the TransCelerate Investigator Registry. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs rely on DrugDev technology to do more trials at Connect with DrugDev on LinkedIn and Twitter.